Quarterly report pursuant to Section 13 or 15(d)

Discontinued Operations - Schedule of Discontinued Operation of Balance Sheet and Operation Statement (Details)

v3.21.1
Discontinued Operations - Schedule of Discontinued Operation of Balance Sheet and Operation Statement (Details) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Cash $ 8,483   $ 31,430
Accounts receivable, net 138,466   151,363
Prepaid expenses and other current assets 858   1,717
Current assets classified as held for sale 147,807   184,510
Property and equipment, net 948   685
Deposits 100,014   100,014
Right of use assets 76,587   100,116
Non-current assets classified as held for sale 177,549   200,815
Accounts payable and checks issued in excess of bank balance 1,905,071   1,911,378
Accrued expenses 1,646,028   1,642,950
Current portion of right-of-use operating lease obligation 76,587   91,166
Current portion of notes payable 216,269   168,751
Current liabilities classified as held for sale 3,843,955   3,814,245
Note payable 82,151   69,267
Right-of-use operating lease obligation   8,950
Liabilities classified as held for sale 82,151   78,217
Revenue from services 118,216 $ 159,509  
Cost (recovery) of services [1] 390 (101,480)  
Gross profit 117,826 260,989  
Operating expenses 331,597 213,484  
Other expense 12,895 28,574  
Provision for income taxes  
(Loss) income from discontinued operations (226,666) 18,931  
Advanced Molecular Services Group and Health Technology Solutions, Inc [Member]      
Cash 6,887   31,294
Accounts receivable, net 138,466   151,363
Prepaid expenses and other current assets 858   1,717
Current assets classified as held for sale 146,211   184,374
Property and equipment, net 948   685
Deposits  
Right of use assets  
Non-current assets classified as held for sale 948   685
Accounts payable and checks issued in excess of bank balance 711,305   726,220
Accrued expenses 1,311,146   1,308,283
Current portion of right-of-use operating lease obligation  
Current portion of notes payable 216,269   168,751
Current liabilities classified as held for sale 2,238,720   2,203,254
Note payable 82,151   69,267
Right-of-use operating lease obligation  
Liabilities classified as held for sale 82,151   69,267
Revenue from services [2] 118,216 159,067  
Cost (recovery) of services 390 8,777  
Gross profit 117,826 150,290  
Operating expenses 283,500 184,368  
Other expense 9,790 25,931  
Provision for income taxes  
(Loss) income from discontinued operations (175,464) (60,009)  
EPIC Reference Labs, Inc. [Member]      
Cash 1,596   136
Accounts receivable, net  
Prepaid expenses and other current assets  
Current assets classified as held for sale 1,596   136
Property and equipment, net  
Deposits 100,014   100,014
Right of use assets 76,587   100,116
Non-current assets classified as held for sale 176,601   200,130
Accounts payable and checks issued in excess of bank balance 1,193,766   1,185,158
Accrued expenses 334,882   334,667
Current portion of right-of-use operating lease obligation 76,587   91,166
Current portion of notes payable  
Current liabilities classified as held for sale 1,605,235   1,610,991
Note payable  
Right-of-use operating lease obligation   8,950
Liabilities classified as held for sale   $ 8,950
Revenue from services 442  
Cost (recovery) of services [1] (110,257)  
Gross profit 110,699  
Operating expenses 48,097 29,116  
Other expense 3,105 2,643  
Provision for income taxes  
(Loss) income from discontinued operations $ (51,202) $ 78,940  
[1] Costs (recovery) of services in 2020 reflect a reduction of $130,000 in the amount previously recorded for laboratory supplies due to the settlement of a claim during the period.
[2] Revenue from services, includes related party revenue of $62,316 and $23,400, respectively.